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Summary 
Aim of the study. The present work aimed to assess the association between cognitive functions, the 
lifetime occurrence of psychotic symptoms, and reported adverse effects of antipsychotic treatments in 
patients with bipolar disorders. 
Methods. In the present work, 44 bipolar disorder inpatients hospitalized in the Affective Disorders Unit 
of the Institute of Psychiatry and Neurology in Warsaw, were investigated. All of them met the criteria of 
remission and were prepared for release from the hospital unit. Twenty-two patients were hospitalized in 
the manic stage of the illness, and 22 were in the depressive stage of illness. Both groups were assessed 
using adequate psychiatric rating scales (HDRS or YMRS and CAMRS) and neuropsychological tests 
(WCST, TMT, Stroop Test and Verbal Fluency Test). 
Results. Patients who had a prior history of psychotic symptoms had poorer verbal functioning in compari-
son to subjects without such a history. However, individuals hospitalized in the manic state of disease, and 
who reported more adverse events after antipsychotic medication during the whole course of illness, had 
worse results in some parameters of executive function measurements in the WCST test, namely occur-
ring in a greater percentage of nonperseverative errors and a lower number of completed categories. 
Discussion. Generally the results confirm findings according to which, patients with the history of psycho-
sis performe worse on neurocognitive tasks. However, the nature of dysfunctions found, generates ques-
tions about its relations with the experience of psychosis and antipsychotic treatment. Conclusion: Dif-
ferent aspects of cognitive dysfunctions may be related to the experience of psychosis and antipsychotic 
treatment in patients with bipolar disorders.
psychotic symptoms / executive functions / verbal functions / bipolar disorders
INTRODuCTION
Numerous studies have confirmed that cogni-
tive decline is observed in individuals with bi-
polar disorders, not only during the acute phas-
es of illness (manic or depressive episodes), but 
also in euthymia [1, 2, 3, 4, 5, 6]. In the whole 
population of bipolar disorder patients, about 
one- third of them experiences at least one psy-
chotic episode during their lifetimes. It is con-
sidered that the history of psychosis has a great 
impact on a patient’s cognitive functioning. Ac-
cording to most of researchers, cognitive dys-
functions in bipolar patients with the experience 
of psychosis, are particularly related to a greater 
impairment of working memory and executive 6	 Agnieszka	Kałwa	et	al.
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functions associated with activation of the pre-
frontal cortex. It results in worse cognitive flexi-
bility, particularly in the ability to change behav-
ior according to environmental circumstances 
during cognitively demanding situations.
The impact of pharmacological treatment is rel-
evant among the many different factors that influ-
ence on the cognitive functioning of bipolar pa-
tients [7]. Although cognitive dysfunctions are 
observed even in unmedicated bipolar individu-
als, different types of pharmacological treatment 
may lead to additional cognitive impairment [8]. 
Not only benzodiazepines taken occasionally or 
antidepressants given during depressive phases, 
but also normothymic treatments (except for lith-
ium, that seems to have no o slight negative im-
pact on cognition) may influence on psychomotor 
slowing and impairment of attention and memo-
ry [9, 10]. The most robust cognitive deficits, par-
ticularly impairment of working memory and ex-
ecutive functions, are considered to be associated 
with antipsychotic pharmacological treatments 
[11, 12].
Cognitive dysfunction in bipolar patients is 
considered to have a similar pattern as in schizo-
phrenic individuals, although it is not as intense 
[13]. However, it is not certain, whether these def-
icits are illness-related (taking into account possi-
of the associations between cognitive functions 
and the lifetime occurrence of psychotic symp-
toms, as well as the reported adverse effects of 
antipsychotic treatment in the bipolar disorder 
patients.
PATIENTS AND METHODS
Researched group
The present study was conducted in the In-
stitute of Psychiatry and Neurology in Warsaw. 
The procedures were approved by the Bioethi-
cal Committee of the Institute of Psychiatry and 
Neurology and were in accordance with the Hel-
sinki Declaration of 1975. All investigated pa-
tients were treated in the Affective Disorders 
Unit of the 2nd Departament of Psychiatry. The 
researched cohort consisted of 44 BD inpatients 
(20 males, 24 females), aged 20-81. Twenty-two 
of the patients (11 males, 11 females) were hospi-
talized in the manic phase of the disease and 22 
individuals (9 males, 13 females) were in the de-
pressive episode of illness. The basic characteris-
tics of the two groups are shown in Tab. 1.
Table 1. Basic characteristics of patients with bipolar disorders hospitalized with symptoms of mania/hypomania (n=22)  
or depression (n=22). Mean values + SD.
BD patients after manic episode 
(n=22)
BD patients after depressive episode 
(n=22)
Age  45 ± (20-81)  57 ± (32-82) 
Years of education 16 ± (11-20) 17 ± (10-20)
Number of hospitalizations 7 ± (1- 41)  4 ± (1-12) 
Duration of current episode 
(weeks)
7 ± (3-20) 12 ± (4-36) 
YMRS CAMRS –average
5 ± (0-17 ) 
7 ± (0-29)
-
Hamilton Depression Scale - 8 ± (1-19) 
ble neurodevelopmental abnormalities and neu-
rodegenerative course of disease alike in schizo-
phrenia processes) and to what extent might be 
caused by antipsychotic treatment.
In the present work, using a neuropsycholog-
ical test battery, we investigated the cognitive 
functions of 44 bipolar disorder patients. The 
aim of this research was to assess the strength 
Only patients with total or partial remission 
according to the diagnosis of the leading psychi-
atrist prior to the planned patient’s release from 
the hospital unit, were included into this study. 
All investigated subjects gave their written in-
formed consent that was received following their 
familiarization with the written information giv-
en to the patient regarding the objectives and 	 Association	of	different	cognitive	domains	with	lifetime	history	of	psychosis	 7
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methods of the study, including the possibility to 
withdraw their consent at any time of research 
procedure. The clinical investigation consisted of 
assessment of the patients using standard psy-
chiatric rating scales and a questionnaire regard-
ing their clinical and psychosocial data. The clin-
ical assessment, was conducted by a specialist 
psychiatrist who was not involved in the treat-
ment process of the investigated patients. Neu-
ropsychological assessments were performed 
by a specialist in clinical psychology, following 
the interview with the psychiatrist. After the pa-
tients were finished participating in the research, 
they had an opportunity to obtain information 
concerning the current condition of their cogni-
tive functions, as well as guidelines for cogni-
tive training. Patients with severe neurological 
and/or significant somatic diseases, that would 
make data interpretation more difficult, addic-
tion to alcohol or other psychoactive substances 
and individuals who refused their consent, were 
excluded from the study.
Most patients from both groups were cur-
rently in polytheraphy. In the first group of pa-
tients (n=22) hospitalized with a diagnosed man-
ic (n=13) or hypomanic (n=9) state of BD, most 
of them (n=18) were currently on a second-gen-
eration antipsychotic treatment (one patient was 
treated with a typical neuroleptic) with an addi-
tional one (n=8) or two (n=10) mood stabilizers. 
Three patients were treated with two mood sta-
bilizers but no antipsychotic drug. Onlyone pa-
tient was in monotherapy with one mood stabi-
lizer. Before the current treatment, most patients 
(n=16) were treated with antipsychotics, mood 
stabilizers and antidepressants. Three patients 
had never taken antidepressants, and two had 
not been treated with an antipsychotic treatment 
before. Twelve patients declared that they were 
taking medications on a regular basis, while 10 
on an irregular basis.
In the second group of patients, hospitalized 
in a depressive state of BD (n=22), all of them 
were currently being treated with antidepres-
sants. Most of these subjects (n=15) were also 
on second-generation antipsychotic treatments 
(only three patients were taking a typical antip-
sychotic), with the exception of one individual, 
additionally were taking one (n=12) or two (n=2) 
mood stabilizers. Six patients were being treat-
ed with antidepressants and one mood stabiliz-
er without an antipsychotic treatment, and one 
patient was in monotherapy with an antidepres-
sant. Before the current treatment, 13 patients 
were taking all the mentioned types of drugs 
(antipsychotics, antidepressants and mood stabi-
lizers), while 8 of them were taking mood stabi-
lizers and antidepressants and one was in mon-
otherapy with only an antidepressant. Fourteen 
patients declared that they were taking their 
medications on a regular basis, while 8 took 
medications on an irregular basis.
The patients’ histories of psychotic symptoms 
and reported adverse effects of antipsychotic 
treatments over the entire course of the disease
In the first group (n=22) hospitalized with di-
agnosed manic (n=13) or hypomanic (n=9) state 
of BD, 9 patients had a history of psychotic 
symptoms over the entire course of the disease 
and, two of them had experienced auditory hal-
lucinations in the past. All of these individuals 
had reported side effects caused by antipsychot-
ics experienced during the entire course of the 
disease. The most frequent symptoms were in-
creased body mass, somnolence and sedation af-
ter taking olanzapine (in 4 patients); increased 
body mass after taking risperidone or pernazine, 
(n=2), with the remaining symptoms including 
menstruation disorders and the Parkinson’s syn-
drome observed after typical antipsychotic treat-
ments.
In the second group of patients hospitalized in 
depressive state of BD (n=22), a history of psy-
chotic symptoms over the entire course of the 
disease was reported by 4 individuals. Six pa-
tients suffered from side effects caused by an-
tipsychotics. Four patients reported somnolence 
and increased body mass after olanzapine, 1 sub-
ject experienced EPS after risperidone, 1 patient 
had low blood pressure after risperidone and 1 
subject had difficulties with concentration after 
quetiapine treatment.
ASSESSMENT
Psychopathological symptom evaluation:
1. The YMRS (Young Mania Rating Scale) [14] 
and the CAMRS (Clinical Adult Mania Rating 
Scale) were used for the assessment of the cur-8	 Agnieszka	Kałwa	et	al.
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rent symptoms of mania in the group of patients 
hospitalized in manic/hypomanic episodes.
2. The HDRS (Hamilton Depression Rating 
Scale) was used in assessing the current depres-
sive symptoms in individuals hospitalized in de-
pressive episodes [15].
Neuropsychological assessment:
1. A computer version by Heaton et al., of the 
WCST (Wisconsin Card Sorting Test) was used 
for the assessment of working memory and ex-
ecutive functions [16].
2. The Trial Making Test was used for assess-
ing psychomotor speed (part A) and visuospa-
tial working memory/set shifting (part B) [17].
3. The Stroop Test was used for evaluating ver-
bal processing speed (part A) and verbal work-
ing memory/ inhibition (part B) [18].
4. The Verbal Fluency Test (Letter FAS and 
Category Test) was used to assess the ability for 
generating words in a 60-second time window.
Statistical analysis
The statistical analyses were performed with 
the statistical package STATISTICA Version 8. 
Due to the small sample size, and because none 
of the variables tested with the Shapiro-Wilk 
Test did met the condition of a normal distribu-
tion, non-parametric tests were used. The mean 
values and standard deviations were calculat-
ed for quantitative traits. R-Spearman correla-
tions were used for examining the significant as-
sociations between independent variables and 
the results of the neuropsychological tests. An 
ANOVA Kruskal-Wallis Test for independent 
groups and a U Mann-Whitney non-parametric 
tests were used for the comparison of groups 
of patients with and without a history of psy-
chotic symptoms as well as with and without re-
ported adverse effects of antipsychotic medica-
tions were counted to verify statistically signifi-
cant differences between the groups. This work 
was powered statistically only to be treated as a 
preliminary study. A Bonferroni correction was 
taken into account.
RESulTS
Neuropsychological tests results
Spearman correlation BD patients after manic episode (n = 22) BD patients after depressive episode (n = 22)
Neuropsychological 
tests
Age Age of onset Education Age Age of onset Education
WCST % PE WCST 
% N-PE
WCST CC 
WCST % CLR
WCST 1st cat 
ns
0.51
ns
-0.52
ns
ns
0.50
ns
-0.57
ns
ns
ns
ns
ns
ns
0.65
ns
-0.73
-0.59
ns
ns
0.74
-0.58
-0.59
ns
ns
ns
0.55
ns
0.52
TMT A
TMT B
0.53
ns
ns
ns
ns
ns
0.55
0.80
0.66
0.82
Ns
ns
Stroop A
Stroop B
Stroop B errors
ns
ns
ns
ns
ns
ns
ns
ns
ns
0.50
0.53
ns
0.42
0.68
ns
Ns
ns
-0.44
VF category test
- correct words
- perseverations
VF letter test 
- correct words
- perseverations
- intrusions
ns
ns
ns
0.45
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
-0.55
ns
-0.60
ns
0.56
-0.56
ns
-0.45
ns
ns
ns
ns
ns
ns
ns
Table 2. Significant (p< 0.05) R-Spearman correlations between psychosocial data, clinical data and the performance  
on neuropsychological tests in bipolar disorder patients after a manic (n = 22) or depressive (n = 22) episode.	 Association	of	different	cognitive	domains	with	lifetime	history	of	psychosis	 9
Archives of Psychiatry and Psychotherapy, 2013; 2 : 5–12
There were no significant differences in the per-
formance on neuropsychological tests between 
“manic” patients compared to “depressed” individ-
uals (tab. 1). Significant correlation between cogni-
tive test performance and age were found in both 
groups of patients. Elderly individuals had more 
perseverative errors, a lower number of correct com-
pleted categories and a lower percentage of concep-
tual-level responses on the WCST, that indicates on 
an age-associated worsening of cognitive flexibility, 
conceptual formation and effectiveness of thinking. 
Elderly patients also had showed worse perform-
ance on the TMT A and B, indicating at poorer psy-
chomotor speed and visuospatial working memo-
ry, and had worse results on the Verbal Fluency Test 
(less correctly generated words and more intrusions 
in the letter part of this test).
In both groups, a later onset age of illness was 
associated with a lower percentage of concep-
tual-level responses in the WCST and worse re-
sults in the TMT A and B.
Later-onset patients from the “depressive” 
group generated significantly fewer words in 
the Verbal Fluency Test. In the same group of pa-
tients after depressive episode, a greater number 
of years of education was correlated with a higher 
number of completed categories in the WCST and 
also a better functioning of verbal working mem-
ory (better performance on the Stroop Test).
In the “manic” group, a higher intensity of 
manic symptoms as measured by the YMRS and 
In the group of patients hospitalized with 
manic episode, we found significant R-Spear-
man correlations between the number of de-
pressive episodes experienced during the entire 
course a patient’s illness and worse performance 
on the neuropsychological tests: a lower number 
of completed categories on the WCST (R=-0.46, 
p<0.05), a higher number of cards needed to 
complete the 1st category on the WCST (R=0.47, 
p<0.05), worse results on the TMT B (R=0.45, 
p<0.05) and a lower number of words in the cat-
egory part of the Verbal Fluency Test (R=-0.66, 
p<0.05).
There were no significant results from the neu-
rophysiological tests related to the type of cur-
rent treatment for a patient and the fact wheth-
er a phase-switch occurred after antidepressant 
treatments.
The history of psychotic symptoms and neuropsy-
chological test performance
As shown in Tab. 3, the history of psychot-
ic symptoms, taking into account the course of 
the disease, was significantly related to patient’s 
cognitive functioning. In the “manic” group in-
dividuals who had ever experienced psychotic 
symptoms, generated significantly fewer words 
in the Verbal Fluency Test (p<0.05) as compared 
to patients without such a history. In the “de-
Table 3. The results of neuropsychological tests performance in patients with and without the history  
of psychotic symptoms. Mean values + SD.
Differences between patients with and without psychotic symptoms significant *p<0.03 and **p<0.05, 
U-Mann Whitney Test.
BD patients after manic episode BD patients after depressive episode
Neuropsycho-
logical test
With psychotic 
symptoms
(n = 9)
Without psychotic 
symptoms 
(n =13)
With psychotic 
symptoms
(n = 4)
Without psychotic 
symptoms 
(n = 18)
 VFT letter test 
- correct words
Stroop A 
27+ (24-31)**
 
ns
35 + (26-38) **
 
ns
ns 
 
25 + (21.5-32) *
ns 
 
24.5 + (21-28) *
CAMRS, correlated with better results (i.e. short-
er performance times) on the Stroop A test (R=-
0.43; p<0.05). In the “depressed” group of pa-
tients, there were no significant correlations be-
tween their scores of the HDRS scale and their 
neuropsychological test results.
pressive” group subjects with a history of psy-
chotic symptoms needed more time to complete 
the Stroop A Test (p<0.03), which is an indica-
tive of worse verbal processing, than individu-
als without a history of psychosis.10	 Agnieszka	Kałwa	et	al.
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Adverse effects of antipsychotics  
and neuropsychological test performance
The U Mann-Whitney test showed statistically 
significant differences (p< 0.01) between groups 
of patients with and without reported adverse 
effects of antipsychotic treatment over the en-
tire course of their disease. These results were 
statistically significant only in the group of pa-
tients hospitalized during manic/hypomanic ep-
isodes. Individuals who reported more adverse 
events after antipsychotics in the whole course 
of illness, at present had more nonperseverative 
errors in the WCST and completed fewercatego-
ries in the WCST (Tab. 4).
polar individuals [21]. Among the different as-
pects of executive dysfunctions, cognitive flexi-
bility is considered to be one of the most impor-
tant traits differentiating individuals with bipo-
lar disorder who have or have not had a history 
of psychotic symptoms [22]. Recent research in 
children at risk for bipolar disorder shows that 
cognitive-flexibility disorders that are associated 
with abnormal activity of the ventrolateral pre-
frontal cortex, can represent a potential marker 
of bipolar disorder [23]. Our work did not con-
firm these findings, because different types of 
cognitive disorders occurred significant in dif-
ferentiating patients with and without the oc-
Table 4. The results of neuropsychological tests performance in patients with and without reported  
adverse effects from antipsychotics during the whole course of illness. Mean values + SD.
Differences between patients with and without adverse effects significant p<0.01 
U-Mann Whitney test.
 BP patients after manic episode  BP patients after depressive episode
Neuropsychologi-
cal test
With adverse  
effects
(n = 9)
Without adverse  
effects 
(n =13)
With adverse  
effects
(n = 4)
Without adverse   
effects 
(n =18)
 WCST % nonper-
severative errors
WCST completed  
categories
 8 ± (7-11)
 
6 ± (6-6)
 20 ± (15-24) 
 
3 ± (1-5) 
 ns
  
ns
 ns
ns
DISCuSSION
The main finding of this study was the asso-
ciation between lifetime psychotic symptom oc-
currence and the present impairment of verbal 
functions, but not executive functions.
The fact that patients with a history of psy-
chotic symptoms performed worse on neuro-
cognitive tasks, is in general accordance with 
the previous studies, though. The majority of 
authors confirm that, only a few of them have 
not found any correlations between lifetime psy-
chotic symptoms’ occurrence and poor current 
cognitive outcomes [19]. The studies confirming 
worse neurocognitive outcomes in psychotic bi-
polar patients indicate the presence of dysfunc-
tions of working memory and executive func-
tions that are associated with the activation of 
the prefrontal cortex [20]. A recent prospective 
study indicated that executive dysfunction is a 
core deficit observed even in clinically stable bi-
currence of psychotic symptoms. Individuals of 
both the “manic” and “depressive” groups, who 
ever had experienced psychotic symptoms in the 
past had, at present, greater verbal dysfunction. 
Patients after mania/hypomania with the histo-
ry of psychotic symptom occurrence generated 
significantly fewer words in the Verbal Fluency 
Test, whereas individuals after depressive epi-
sode who had experienced psychosis, had worse 
verbal processing speed.
The broader meaning of verbal dysfunctions 
in bipolar disorders is generally not emphasized 
as much as in discussions of schizophrenia [24]. 
However, the latest studies by Meesters et al. 
[25] indicate that similar dysfunction profile is 
observed in older individuals diagnosed as bipo-
lar I subjects as well as in remitted and non-re-
mitted schizophrenic patients. The dysfunction 
profile includes not only executive dysfunction, 
butalso memory and verbal fluency deficits. Pa-
tients included into the Meesters’ et al. study 	 Association	of	different	cognitive	domains	with	lifetime	history	of	psychosis	 11
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were treated with antipsychotic medications, 
however, this was not an independent variable 
in the analyses of the neuropsychological tests. 
In our work, executive function disorders were 
significantly different between groups when tak-
ing into account the patients’ histories of report-
ed side effects of antipsychotic treatment. Sub-
jects hospitalized after mania/hypomania, and 
who reported more adverse events after antip-
sychotic medication during the whole course of 
their disease, had, in the present study, great-
er executive function disorders that resulted in 
poorer conceptualization (fewer categories com-
pleted in the WCST) and more intense attention 
disorders (a greater percentage of nonpersever-
ative errors). It could be hypothesized that the 
“frontal” dysfunctions observed in BD patients 
in the cited studies was not only associated with 
psychotic symptom occurrence itself, but might 
also be seen as an effect of the response for an-
tipsychotic pharmacological treatment. One 
could also suppose that different aspects of ex-
ecutive dysfunction may be specific to each ef-
fect of antipsychotic treatment rather than devi-
ations of the “core” executive impairment gen-
erally observed in bipolar disorder patients. In 
the present study, executive domains other than 
cognitive flexibility (as measured by the number 
of perseverative errors in the WCST) were more 
impaired in patients reporting adverse effects of 
antipsychotic treatment. Our results correspond 
with some findings of Torrent et al.[26] who ex-
amined the results of the neurocognitive tests of 
119 bipolar individuals: 68 patients treated with 
antipsychotics and 16 unmedicated. The authors 
used a wide battery of neuropsychological tests 
and, confirmed cognitive decline in bipolar pa-
tients relative to healthy controls. They found 
that individuals who were not in a pharmacolog-
ical treatment had significantly better cognitive 
outcomes, possibly indicating that cognitive dys-
function can be understood as a certain side ef-
fect of treatment response. However, the authors 
also considered that the group of unmedicated 
patients could have been a biased sample with 
better outcome. Compared to pharmacologically 
untreated individuals, patients on antipsychot-
ic medication had worse results in semantic ver-
bal fluency and verbal memory measures. That 
finding is consistent with our results indicating 
at verbal dysfunctions in patients with the his-
tory of psychotic symptoms, but not with exec-
utive dysfunctions differentiating patients with 
and without a history of adverse effects of an-
tipsychotic treatment. Further prospective lon-
gitudinal studies should be conducted in order 
to explain whether and to what extent different 
types of cognitive dysfunctions are associated 
with psychotic symptom occurrence and when 
it should be understood as an evident effect of 
antipsychotic treatment.
Some significant age-related and educational-
level-related between-patient differences in neu-
ropsychological test performance, as well as the 
age of illness onset and sex-related differences 
(patients with a later age of onset and males per-
formed worse on the Verbal Fluency Test) in the 
researched group, might be explained as simply 
the ageing of cognitive function [27]. However, 
worse neurocognitive outcomes were also relat-
ed to the current intensity of the psychopatho-
logical symptoms in both manic/hypomanic pa-
tients as well as in depressive individuals. These 
data are consistent with the findings of other 
studies describing worse cognitive outcomes in 
BD patients who still had current depressive [28, 
29, 30] or manic [31, 32, 33, 34] symptoms.
lIMITATIONS
The present work should be treated as a pre-
liminary study that must be interpreted in light 
of its limitations. A relatively small sample of 
patients were investigated, with significant be-
tween-patient age bias. Some important data 
(such as the reporting of their history of psy-
chotic symptoms and of the adverse effects of 
antipsychotic treatments) were just reported by 
the investigated subjects, and could not all of 
them were possible to be confirmed by the medi-
cal documentation. Although the individuals in-
cluded into the study were considered to be re-
mitted by leading highly qualified doctors and 
assessed by other an independent psychiatrist 
according to standard psychiatric rating scales, 
the patients’ states of remission could vary be-
tween different individuals, due to the lack of a 
precise set of criteria for remission in bipolar in-
dividuals. Because the majority of patients were 
in polytherapy, the assessment of the influence 
of antipsychotic medication on cognition is very 12	 Agnieszka	Kałwa	et	al.
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limited. Lastly, because some of the investigated 
patients self-reported incomplete compliance, it 
is worth to indicate that this fact could addition-
ally influence on the results.
CONCluSION
In the present work, a lifetime history of psy-
chosis in bipolar disorder patients was associat-
ed with verbal-function impairment. Working 
memory and executive function deficits, which 
in most studies are considered to be associated 
with the history of psychosis, were related to the 
adverse effects of antipsychotic treatments. The 
results suggest that psychotic symptom occur-
rence and the influence of antipsychotic treat-
ments may be associated with the dysfunction 
of distinct cognitive domains.
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